News Releases

December 12, 2018
Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines
– Good Manufacturing Process (GMP) infrastructure enables advancement of clinical programs through early and mid-phase studies – – Capabilities support production of both liquid and solid oral formulations – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- Synlogic, Inc....
November 20, 2018
Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 30th Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday, November...
November 13, 2018
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates
– Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019 – – Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019 – – Management to host conference call and webcast at...
November 12, 2018
Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
- Data support ongoing evaluation of Synthetic Biotic TM SYNB1020 for the potential treatment of hyperammonemia - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2018-- Synlogic, Inc.  (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial...
November 7, 2018
Synlogic Announces Third Quarter 2018 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018 . The press release will be followed by a conference call at 5:00 p.m....
November 6, 2018
Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
– Data highlight the differential advantages of Synthetic Biotic approach designed to activate the local innate immune system for the potential treatment of a variety of solid tumors – – Company will webcast Investor and Analyst event at 12:30 pm ET , Saturday, November 10, 2018 , to discuss...
November 1, 2018
Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
- Presentations to feature key opinion leaders and expand on preclinical data from Synlogic’s first immuno-oncology candidate, accepted for presentation at SITC 2018 - - Company to webcast event, beginning at 12:30 p.m. ET on Saturday, November 10, 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov....
October 2, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan , M.B., B.Ch., as president and chief executive officer of...
September 25, 2018
Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare...
September 4, 2018
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)

– Data demonstrate statistically significant dose-dependent effects on SYNB1618 activity-associated biomarkers, supporting further development of SYNB1618 – – SYNB1618 dose established for treatment arm of ongoing Phase 1/2a study in patients with PKU; top-line data expected in mid-2019 – – Company

...
August 29, 2018
Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C.

...
August 13, 2018
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
– Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models – – Clinical data expected in 2018 from healthy volunteer cohorts of ongoing Phase 1/ 2a study of SYNB1618; data from patients with phenylketonuria (PKU) in...
Displaying 49 - 60 of 115